Literature DB >> 16378162

Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.

Mucahit Yetim1, Ozcan Ozeke, Bulent Deveci, M Timur Selcuk, Dursun Aras.   

Abstract

Combined activated protein C resistance and dilated cardiomyopathy result in a multiplicative effect on thrombosis risk. However, it is not known that whether there is an association with activated protein C resistance and dilated cardiomyopathy. We present a 18-year-old patient with dilated cardiomyopathy, who exhibited multi-chamber intracardiac thrombi on transthoracic echocardiography associated with activated protein C resistance. Our cases emphasizes that patients with cardiac thrombosis before adulthood should be screened for an underlying coagulation abnormality besides underlying cardiac disorders.

Entities:  

Mesh：

Year:  2005        PMID： 16378162     DOI： 10.1007/s10554-005-7437-4

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN： 1569-5794            Impact factor:   2.357


  10 in total

Review 1.  The roles of protein C and thrombomodulin in the regulation of blood coagulation.

Authors:  C T Esmon
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

Review 2.  Does heart failure confer a hypercoagulable state? Virchow's triad revisited.

Authors:  G Y Lip; C R Gibbs
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

3.  Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Authors:  P M Ridker; R J Glynn; J P Miletich; S Z Goldhaber; M J Stampfer; C H Hennekens
Journal:  Ann Intern Med       Date:  1997-04-01       Impact factor: 25.391

Review 4.  Arterial embolism to the upper extremity in a patient with factor V Leiden mutation (APC resistance)--a case report and review of the literature.

Authors:  B Dorweiler; A Neufang; W Kasper-Koenig; H Schinzel; W Schmiedt; H Oelert
Journal:  Angiology       Date:  2003-01       Impact factor: 3.619

Review 5.  Inherited risk factors for venous thromboembolism: implications for clinical practice.

Authors:  Paul M Ridker
Journal:  Clin Cornerstone       Date:  2002

6.  Anticoagulant protein C pathway defective in majority of thrombophilic patients.

Authors:  J H Griffin; B Evatt; C Wideman; J A Fernández
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

7.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

8.  Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.

Authors:  Katharina Middendorf; Peter Göhring; Tanya Y Huehns; Dietrich Seidel; Gerhard Steinbeck; Sigrid Nikol
Journal:  Am Heart J       Date:  2004-05       Impact factor: 4.749

9.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.